| Description | Emtricitabine, a potent nucleoside reverse transcriptase inhibitor, is employed for managing HIV infection. Emtricitabine S-oxide, also known as Emtricitabine sulfoxide, represents a significant degradation byproduct of Emtricitabine. |
| In vitro | Emtricitabine degrades over 51%, 13% and 53% during acid, base and oxidative degradation respectively followed by formation of three major degradation products (Degradant-I to Degradant-III).Emtricitabine, an antiretroviral agent is used to evaluate degradation pathways under different stress conditions in order to identify degradation products as prescribed by ICH guidelines. |
| Synonyms | Emtricitabine Degradant-III, Emtricitabine sulfoxide |
| molecular weight | 263.25 |
| Molecular formula | C8H10FN3O4S |
| CAS | 152128-77-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. A Prakash, et al. Forced degradation study of emtricitabine for evaluation of genotoxic impurity in active pharmaceutical ingredient's (API) shelf life. World Journal of Pharmacy and Pharmaceutical Sciences (2015), 4(7), 1909-1919. |